.png "Insmed (NASDAQ: INSM)")
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM) today and set a price target of $52. The company’s shares closed yesterday at $31.30, close to its 52-week high of $32.16.
Fein observed:
“Our price target of $52/share is based on: (a) $51/share, as a 35x multiple of taxed and diluted FY28 GAAP EPS of $7.58 discounted back to and (b) an NPV of $52/share, (discount rate 12.0%, growth rate 2%), with both methods arriving at this target. Risks to our investment thesis and target price include: (1) failure of ALIS in the (2) failure of ALIS to achieve peak commercial revenue estimates in our model due to market size, penetration rates and/or pricing or other limiting factors.”
According to TipRanks.com, Fein is a 5-star analyst with an average return of 10.2% and a 49.8% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and Proteostasis Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Insmed with a $42.50 average price target, which is a 35.8% upside from current levels. In a report issued on March 26, Stifel Nicolaus also reiterated a Buy rating on the stock with a $43 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $32.16 and a one-year low of $11.31. Currently, Insmed has an average volume of 864.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insmed, Inc. operates as a biopharmaceutical company. It focus developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening.
